Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III
Berlin, Germany – January 26, 2023 ProBioGen today announced that a Novartis clinical candidate using its antibody-dependent cellular cytotoxicity (ADCC) technology, GlymaxX, has..
ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production
Berlin, Germany – January 18, 2023 ProBioGen is announcing another important clinical milestone for its proprietary viral vector and vaccine production cell line AGE1.CRpIX®. Our..
ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology
Berlin, Germany – January 10, 2023 ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology...
ProBioGen Co-Develops New Freedom™ ExpiCHO-S™ Cell Line Development Kit
Berlin, Germany – October 27, 2022 Following the success of the Gibco™ Freedom™ CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific have teamed up again to..
ProBioGen Celebrates "A New Dawn in Biotechnology"
Symposium Honors Chief Scientific Officer, Dr. Volker Sandig Berlin, Germany – September 30, 2022 The biotechnology firm ProBioGen held the symposium "A New Dawn in Biotechnology:..
ProBioGen Receives Employer of the Future and Top Service Awards
Biopharma Company Recognized at DIGITAL X 2022 Berlin, Germany – September 13, 2022 Today, the Berlin-based biopharmaceutical company ProBioGen received the Employer of the Future..
ProBioGen and City of Hope Announce Commercial License Agreement to Use AGE1.CR.pIX® Vaccine Manufacturing Platform for Cytomegalovirus (CMV) Vaccine
Berlin, Germany and Los Angeles, USA, September 7, 2022 ProBioGen and City of Hope, one of the largest cancer research and treatment organizations in the United States, announced..
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Oct 10, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-3.jpeg)
ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)
Sep 16, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-1.jpeg)
ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services
May 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
